Comparable Company Analysis: DocuSign Inc. (DOCU), Sanofi (SNY)

You should consider shares of DocuSign Inc. (NASDAQ:DOCU) and Sanofi (NASDAQ:SNY) if you are looking for a great stocks to invest in. Starting with the DOCU shares, which traded at $70.68 at the close of the recent session, gaining 1.09%. On Tuesday, the company’s shares shed $0.76 from its value which represented in intraday trading. The stock is now 69.25% higher in year-to-date (YTD) trading. DOCU’s intraday high was $70.87 while its lowest price touched $66.97. The stock’s 52-week high price is $73.22, which means the current price is at -3.47%. In terms of trading activity, the daily trading volume fell to 2003264 against 200-day average trading volume of 2,565,730 shares.

What are analyst forecasts for DocuSign Inc. (NASDAQ:DOCU)?

At a consensus rating of 4.62, DOCU is trending as a streaking Strong Buy, as it has been the case a month ago when 11 analysts called it a Strong Buy. Two months ago, 11 analysts recommended, on average, that DOCU stock is a Strong Buy. The Technology company’s shares’ overall bullish trend saw it close higher on Tuesday compared to its opening price of $67.69 on the day.

Forecasts for DocuSign Inc. (NASDAQ:DOCU) give the stock a fair value for the growth of 5.76% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $75.00, which means the price per share could rise by nearly $4.32. The price range target is between a low of $62.00 and a high of $93.00. The stock would need to gain by about $24.0 to hit the estimated high or 0.51% from its 12-month low.

The consensus among 14 analysts is that it is a good time for one to Buy in the DocuSign Inc. 11 analysts rate DOCU as a Buy, with 0 of 14 analysts rate it as a Sell. 0 have valued the stock as Overweight and 3 have recommended that investors Hold.

DocuSign Inc. (NASDAQ:DOCU) Upgrades and Downgrades

In terms of rating changes, JMP Securities on November 21, 2019, Reiterated DocuSign Inc. (DOCU) at Mkt Outperform. They believe the stock could reach $75 in the near term. Analysts at Piper Jaffray have assigned a Neutral rating for the stock in their research note on November 08, 2019 with an estimated price target of $75. Moreover, Evercore ISI analysts issued a rating of Outperform for the stock on November 04, 2019, giving it a price target of $80 for the next 12 months. On October 16, 2019, the stock earned a Outperform rating due to an analyst call from Wedbush, while analysts from RBC Capital Mkts on October 02, 2019 suggested that the stock is Outperform.

Sanofi (NASDAQ:SNY) adds -$0.27 on Tuesday

The SNY stock has risen 4.93% year-to-date and is currently trading at $45.55, which is -4.04% below its 52-week high. The company shares lost -0.59% on the day and have risen nearly 13.87% off a low hit. At current levels, Sanofi has a valuation of about $40.66B. As of 12/03/19, this stock has fallen -2.88% during the week and closed at $45.82 in the previous session. However, recent Sanofi stock performance shows that SNY shares are -0.20% down over the last month, and 1.83% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $0.65, with the trailing 12-month share earnings at $1.39. The ratio is expected to be up by 1.50% for the current year 2019 and 5.80% for next year. Over the next 5-year period, earnings per share will be 7.70%. But will the SNY stock surprise in the current quarter results, where the $0.96 actual EPS reported on 9/29/2019 surprised by 0.00% or was lower by $0 from the estimated $0.96.

Sales Growth to climb 4.00% for the year

How well will Sanofi perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $10.56B and $10.84B in current quarter sales. The consensus estimated for the current quarter is $10.7B from sales. Forecasts for this fiscal year are between $39.73B and $41.5B and the consensus estimate for sales is at $40.59B. SNY has its next quarter sales estimates at between $9.9B and $9.9B, with the quarter-over-quarter growth estimates at 5.50% and the annual growth forecast for the year at 4.00%.

Who owns shares in Sanofi (SNY)?

Let’s briefly focus on the share ownership of the Sanofi (NASDAQ:SNY) stock, where we find that 7.73% of shares are held by institutions. Dodge & Cox Inc tops the list of institutional owners as it is holding 60.87 million shares or 22.84% of shares outstanding. Fisher Asset Management, LLC and Barrow, Hanley Mewhinney & Strauss, LLC held 17.38 million and 10.44 million representing 6.52% and 3.92% respectively at the close of the last trading session. As of Sep 29, 2019, FMR, LLC accounted for 8.0 million shares at over 370.48 million. This represented 3.00% of shares outstanding. Invesco Ltd. held 7.77 million shares at over 359.89 million representing 2.91% of shares outstanding.